AxoGen, Inc. (NASDAQ:AXGN) Q3 2025 Earnings Call Transcript
Operator: Good morning. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer.
Axogen Inc. (AXGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Soleus Capital Guy Levy | 1,726,553 | $30,801,706 | +19% | 1.55% |
| 2. | Balyasny Asset Management Dmitry Balyasny | 1,379,642 | $24,612,813 | -29% | 0.03% |
| 3. | Armistice Capital Steven Boyd | 1,200,000 | $21,408,000 | +8% | 0.32% |
| 4. | DAFNA Capital Management Nathan Fischel | 742,282 | $13,242,311 | +1% | 3.27% |
| 5. | Parkman Healthcare Partners Greg Martinez | 501,832 | $8,952,683 | -26% | 0.93% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.50 | 2,525 | $26,512.50 | 25,082 | 2024-08-08 | Filing | |
| $6.22 | 10,000 | $62,240.00 | 80,342 | 2023-09-06 | Filing | |
| $6.56 | 10,000 | $65,600.00 | 10,000 | 2023-08-23 | Filing | |
| $6.11 | 10,000 | $61,100.00 | 68,259 | 2023-08-16 | Filing | |
| $14.10 | 14,170 | $199,797.00 | 15,535 | 2019-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.02 | 3,591 | $86,248.64 | 100 | 2025-11-11 | Filing | |
| $24.01 | 19,227 | $461,640.27 | 100 | 2025-11-10 | Filing | |
| $24.01 | 5,347 | $128,370.78 | 100 | 2025-11-06 | Filing | |
| $24.05 | 11,431 | $274,892.69 | 100 | 2025-11-05 | Filing | |
| $23.00 | 18,248 | $419,704.00 | 100 | 2025-10-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,805,730 | $103,574,223 | 9.76% | |
| 2. | 3,609,158 | $64,387,378 | 0% | |
| 3. | 2,679,398 | $47,800,461 | 0% | |
| 4. | 2,429,841 | $43,348,363 | 0% | |
| 5. | 1,958,406 | $34,937,963 | 0.65% |
News See All
Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21
Axogen, Inc. (NASDAQ:AXGN) is one of the best medical device stocks to buy according to analysts. On August 6, Raymond James analyst Jayson Bedford lowered the firm’s price target on Axogen, Inc.
12 Best Medical Device Stocks to Buy According to Analysts
On July 7, CNBC’s Chery Kang and Elaine Yu talked about China’s imposition of reciprocal tariffs on the import of medical devices from the European Union.
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript
Operator: [Audio Gap] Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer.
Axogen Showcases Nerve Repair Vision at Goldman Sachs
Axogen, Inc. (NASDAQ:AXGN) is among the best growth stocks to invest in for the next 5 years. On June 11, 2025, Axogen, Inc.
15 Best Growth Stocks to Invest in for the Next 5 Years
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.
AxoGen, Inc. (NASDAQ:AXGN) Q1 2025 Earnings Call Transcript
Operator: Good morning, everyone.
AxoGen, Inc. (NASDAQ:AXGN) Q4 2024 Earnings Call Transcript
Operator: Good morning everyone.
AxoGen, Inc. (NASDAQ:AXGN) Q3 2024 Earnings Call Transcript
Operator: Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer.
Hedge Fund Resource Center Billionaire Hedge Funds
